Welcome to our dedicated page for Synaptogenix news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on Synaptogenix stock.
Synaptogenix, Inc. (NASDAQ: SNPX) is an emerging clinical-stage biopharmaceutical company focused on the development of innovative therapies for neurodegenerative diseases. The company leverages its lead drug candidate, Bryostatin-1, in addressing various challenging conditions such as Alzheimer's disease, Fragile X syndrome, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and traumatic brain injury.
Synaptogenix is currently conducting clinical and preclinical trials to evaluate the efficacy and safety of Bryostatin-1. This drug, which activates protein kinase C (PKC), has shown potential in promoting synaptic growth, reducing inflammation, and aiding cognitive function. Recent achievements include partnering with the Cleveland Clinic for a Phase 1 trial of Bryostatin-1 aimed at cognitive impairment in MS and discovering potential benefits in treating ALS.
The company has also gained significant attention from the research community, with notable publications in esteemed journals like the Journal of Alzheimer's Disease and involvement in high-profile scientific forums. Leveraging its substantial financial resources, Synaptogenix continues to explore additional therapeutic avenues and partnerships, including a significant stake in Cannasoul Analytics, aiming to develop cannabinoid-based treatments.
Synaptogenix’s financial health is stable, bolstered by approximately $35.8 million as of March 31, 2023, and $33 million as of June 30, 2023, ensuring continuous development of its drug candidates. The company's recent reverse stock split aligns with strategic efforts to maintain NASDAQ compliance and increase stock value.
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will compare these analogs with Bryostatin in SCI treatment. Synaptogenix holds exclusive rights to these PUFA analogs, which have shown promise in earlier pre-clinical testing for various neurodegenerative diseases. Like Bryostatin-1, these analogs activate the enzyme PKC epsilon (PKC ε), but at a different site, potentially offering a next-generation treatment for neurodegenerative conditions.
Synaptogenix has received FDA authorization for an Investigational New Drug (IND) application to conduct a clinical trial on Bryostatin-1, a potential treatment for multiple sclerosis (MS).
The trial, which will be held at the Cleveland Clinic Neurological Institute's Mellen Center, aims to evaluate the drug's effects on synaptic health and cognitive function using advanced 7-tesla MRI technology.
Synaptogenix highlights the need to address cognitive decline in MS, with the trial fully funded and expected to start soon.
Preclinical data shows that Bryostatin-1 may enhance synapse health, reduce inflammation, and prevent neurological degradation.
Synaptogenix has a strong financial position with $26.3 million in cash, supporting ongoing and future research efforts.
Synaptogenix, Inc. (Nasdaq: SNPX) praises the DEA's proposal to reclassify cannabis as a Schedule III drug, potentially benefitting its partner Cannasoul for cannabinoid-based drug discovery. The move would de-risk drug development, streamline regulatory pathways, and enhance clinical development for cannabis-based therapeutics.
FAQ
What is Synaptogenix, Inc. focused on?
What are the main conditions Synaptogenix targets with Bryostatin-1?
What recent collaboration has Synaptogenix entered into?
What financial resources does Synaptogenix have to fund its operations?
What recent study findings support the potential of Bryostatin-1?
What is the significance of Synaptogenix's partnership with Cannasoul Analytics?
How is Synaptogenix ensuring compliance with NASDAQ regulations?
What are the potential benefits of Bryostatin-1 in Alzheimer's disease?
Has Synaptogenix received any accolades or recognition in the scientific community?
What are the forward-looking statements and risks related to Synaptogenix?
